Detection of circulating immune complexes in acute non-lymphatic leukaemia: is it reliable?

Acta Haematologica
G RossiG Marinone

Abstract

The in vivo and in vitro phagocytic ability of leukaemic cells and the serum levels of circulating immune complexes (CIC) have been evaluated in 11 patients affected by acute non-lymphatic leukaemia (ANLL). High levels of serum CIC were detected in 17% of the cases showing phagocytic ability and in 80% of the cases lacking phagocytic ability (p less than 0.05). In 3 patients serum CIC determinations were negative while immunoglobulins with complement-fixing ability were detected in the cytoplasm of leukaemic cells indicating in vivo phagocytosis of CIC. These results suggest that leukaemic cells may sometimes interfere through their phagocytic ability on the detection of CIC in the serum. Therefore, the clinical and prognostic value of serum CIC in ANLL seems questionable.

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.